Lipid-lowering agent-2 (Compound 14d) exhibits oral efficacy as a lipid-lowering agent with an EC50 of 0.06 µM. It works by inhibiting lipid synthesis and activating the AMPK signaling pathway, contributing to its anti-obesity effects. Additionally, Lipid-lowering agent-2 suppresses food intake in mice, enhances glucose metabolism, and reduces body weight and adipose tissue in mice induced by a high-fat diet (HFD).
Target-Kategorie:
AMPK
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
